Debilitating Pain and Fractures A Rare Case of Hypophosphatemic Osteomalacia with Concomitant Vitamin D Deficiency in Neurofibromatosis Type 1
Hypophosphatemic osteomalacia is a rare form of metabolic bone disorder in neurofibromatosis type 1 (NF1). The exact disease mechanism of this disorder in NF1 is yet to be established. We present a 44-year-old female known to have NF1, who presents with debilitating bone pain, weakness and multiple fractures. Laboratory investigations showed
persistent hypophosphatemia with renal phosphate wasting suggestive of hypophosphatemic osteomalacia. She also had concomitant vitamin D deficiency which contributed to the disease severity. Medical therapy with oral phosphate and vitamin D improved her symptoms without significant changes in fracture healing or phosphate levels.
Elefteriou F, Kolanczyk M, Schindeler A, Viskochil DH, Hock JM, Schorry EK, et al. Skeletal abnormalities in neurofibromatosis type 1: Approaches to therapeutic options. Am J Med Genet. 2009; 149A(1):2327–38. https://www.ncbi.nlm.nih.gov/pubmed/19764036. https://doi.org/10.1002/ajmg.a.33045.
Kumar S, Kushwaha P, Bharti N, et al. Elevated FGF23 in a patient with hypophosphatemic osteomalacia associated with neurofibromatosis type 1. Bone. 2019;129:115055. https://www.ncbi.nlm.nih.gov/pubmed/31476437. https://doi.org/10.1016/j.bone.2019.115055.
Gupta A, Dwivedi A, Patel P, Gupta S. Hypophosphatemic osteomalacia in von Recklinghausen neurofibromatosis: Case report and literature review. Indian J Radiol Imaging. 2015;25(1):63–6.
Konishi K, Nakamura M, Yamakawa H, et al. Case report: Hypophosphatemic osteomalacia in Von Recklinghausen neurofibromatosis. Am J Med Sci.1991;301(5):322-8. https://www.ncbi.nlm.nih.gov/pubmed/1902351.
Abdel-Wanis M, Kawahara N. Hypophosphatemic osteomalacia in neurofibromatosis 1: Hypotheses for pathogenesis and higher incidence of spinal deformity. 2002;59(2):183–5. https://www.ncbi.nlm.nih.gov/pubmed/12208207. https://doi.org/10.1016/s0306-9877(02)00254-2.
Michigami T. Skeletal mineralization : Mechanisms and diseases. Ann Pediatr Endocrinol Metab. 2019;24(4):213-9. https://www.ncbi.nlm.nih.gov/pubmed/31905439. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944863. https://doi.org/10.6065/apem.2019.24.4.213.
Jagtap VS, Sarathi V, Lila AR, Bandgar T, Menon P, Shah NS. Hypophosphatemic rickets. India J Endocrinol Metab.2012;16(2):177-82. https://www.ncbi.nlm.nih.gov/pubmed/22470852. https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC3313733. https://doi.org/10.4103/2230-8210.93733.
Collins MT, Hartley IR, Florenzano P. Tumor-induced osteomalacia. Principles of Bone Biology. Elsevier Inc.; 2020. Targeted disruption of NF1 in osteocytes increases FGF23 and osteoid with osteomalacia-like bone phenotype. J Bone Miner Res. 2017;32(8):1716-26. https://www.ncbi.nlm.nih.gov/pubmed/28425622. https://doi.org/10.1002/jbmr.3155.
Insogna KL, Briot K, Imel EA, et al. A Randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with x-linked hypophosphatemia: Week 24 primary analysis. J Bone Miner Res. 2018;33(8):1383-93. https://www.ncbi.nlm.nih.gov/pubmed/29947083. https://doi.org/10.1002/jbmr.3475.
Imel EA, Glorieux FH, Whyte MP, et al. Burosumab versus conventional therapy in children with x-linked hypophosphataemia: A randomised, active-controlled, open-label, phase 3 trial. Lancet. 2019;393(10189):2416-27. https://www.ncbi.nlm.nih.gov/pubmed/31104833. https://doi.org/10.1016/S0140-6736(19)30654-3.
Jan De Beur S, Miller P, Weber T, et al. OR13-1 Burosumab improves the biochemical, skeletal, and clinical symptoms of tumor-induced osteomalacia syndrome. J Endocr Soc . 2019;3(Suppl 1):OR13. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554835. https://doi.org/10.1210/js.2019-OR13-1.
Copyright (c) 2020 Shamharini Nagaratnam, Malathi Karupiah, Norlaila Mustafa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of the ASEAN Federation of Endocrine Societies is licensed under a Creative Commons Attribution-NonCommercial 4.0 International. (full license at this link: http://creativecommons.org/licenses/by-nc/3.0/legalcode).
To obtain permission to translate/reproduce or download articles or use images FOR COMMERCIAL REUSE/BUSINESS PURPOSES from the Journal of the ASEAN Federation of Endocrine Societies, kindly fill in the Permission Request for Use of Copyrighted Material and return as PDF file to email@example.com or firstname.lastname@example.org.
A written agreement shall be emailed to the requester should permission be granted.